Biosimilars Archives

In Depth 16 Jun 2025

Did Novo open the Canadian market to GLP-1 generics?

Find out if Novo’s GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a small fee?

June 16, 2025 - 8 minutesmins - By Jules Adam

Best in Biotech 5 Dec 2024

Five biosimilar companies you should know about

Discover five biosimilar companies creating affordable versions of blockbuster drugs and hoping to capitalize on the upcoming patent cliff.

December 5, 2024 - 11 minutesmins - By Willow Shah-Neville

In Depth 7 Mar 2024

Can AbbVie’s legacy live beyond its once best-selling drug Humira?

The sales of AbbVie’s Humira, once a best-seller, have dropped. Now, with a new CEO announced, things are about to change for the company.

March 7, 2024 - 8 minutesmins - By Roohi Mariam Peter

Podcast 9 Feb 2024

Biosimilars and what’s new in cell and gene therapies

This week on the podcast, we have a conversation with Fran Gregory, vice president of Emerging Therapies at Cardinal Health. The discussion covers the company’s role in healthcare, biosimilars, the latest in cell and gene therapies, and Advanced Therapies Week. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals and a global manufacturer and […]

February 9, 2024

News and Trends 20 Oct 2022

Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market

Alvotech and the JAMP Pharma Group have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech. The companies have added two biosimilar candidates from Alvotech’s pipeline: AVT16, a proposed biosimilar to an undisclosed immunology product and AVT33, a proposed biosimilar to an undisclosed oncology product. “We are very pleased to be expanding […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium

The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) has received a major grant from the Food & Drug Administration (FDA) in support of biosimilars research. The award provides $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review. The study, “Improving the Efficiency of […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

More News! 17 Oct 2018

The EU Patent of the Best Selling Drug Has Expired, What Does it Mean for Biotech?

AbbVie’s Humira, a treatment for inflammatory disease and the world’s best-selling drug, is no longer patent-protected in the EU. Competitors are already taking advantage of it. Humira is an antibody drug, called adalimumab, that has been topping the lists of best-selling drugs for years. Last year alone, it made over €15B in sales worldwide. The […]

October 17, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Sep 2017

German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval

Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed in Europe. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Cyltezo for approval, moving it closer to the market and offering a new treatment for a range of inflammatory diseases. The biosimilar drug of adalimumab (Humira) could treat […]

September 18, 2017 - 1 minutemin - By Alex Dale

samsung bioepis imraldi humira adalimumab biosimilar tnf a

News and Trends 28 Aug 2017

Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody

Samsung Bioepis has announced the European Commission approved Imraldi, a biosimilar of AbbVie’s Humira (adalimumab), which has topped revenue charts for years. Samsung Bioepis’ Imraldi has now marketing authorization in the EU as a biosimilar of Humira (adalimumab) for the treatment of over 10 inflammatory indications, including rheumatoid arthritis, psoriasis, Crohn’s disease and ulcerative colitis. This makes […]

August 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

biosimilars market novartis sandoz roche boehringer ingelheim

News and Trends 16 Aug 2017

Biosimilars Struggle to Substitute Brand-Name Drugs

Despite bringing a significant price reduction, biosimilars might lag in taking over the market of the drugs they copy because of exclusivity policies set up by the owners of brand-name drugs. A report in Bloomberg Markets yesterday highlights the case of Inflectra, a biosimilar from Pfizer that imitates Johnson & Johnson’s rheumatoid arthritis blockbuster Remicade (infliximab). Despite bringing a price reduction […]

August 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Feb 2017

Biosimilars set to take on Oncology after a new Market Authorization

The European Commission has approved Truxima, the world’s first biosimilar monoclonal antibody (mAb) with an oncology indication. Based in South Korea, Celltrion Healthcare is setting foot in the European oncology market with the approval of Truxima, a biosimilar to Roche’s Mabthera (rituximab). The European Commission has approved the antibody for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis […]

February 23, 2017 - 3 minutesmins - By Melanie De Almeida

More News! 8 Feb 2017

The FDA lays down Laws of Interchangeability: New Era for Biosimilars?

The new guidelines from the FDA on interchangeability may bring the US biosimilar market up to speed and a new opportunity for European companies. Though the US has long been seen as the most promising market for biosimilars due to the size of the market and high drug prices driving an interest in more affordable options, […]

February 8, 2017 - 4 minutesmins - By External Contributor

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Biosimilars

Did Novo open the Canadian market to GLP-1 generics?

Five biosimilar companies you should know about

Can AbbVie’s legacy live beyond its once best-selling drug Humira?

Biosimilars and what’s new in cell and gene therapies

Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market

FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium

The EU Patent of the Best Selling Drug Has Expired, What Does it Mean for Biotech?

German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval

Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody

Biosimilars Struggle to Substitute Brand-Name Drugs

Biosimilars set to take on Oncology after a new Market Authorization

The FDA lays down Laws of Interchangeability: New Era for Biosimilars?

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!